AR and prostate cancer: Recently, Chakravarthi and colleagues identified a fusion occurring in around 30% of primary prostate cancer cases and involving the AR target gene KLK4 as a 5′ partner and the non-coding pseudogene KLKP1 (Chakravarthi et al., 2019).